Tag Archive for: fibrosis

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

/in

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome. The new CAB brings unparalleled expertise in basement membrane biology, genetic kidney diseases, and glomerular disorders, providing critical guidance as Fibrocor advances its first-in-class pipeline towards […]

Read more

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

/in

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases,  today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]

Read more

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.

/in

– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]

Read more

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

/in

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment options Fibrocor and MSRD intend […]

Read more